It looks like you have an older browser that is not supported by this site. Please click here to update.
The Indiana Department of Health’s LTC Medical Director, Dr. Vuppalanchi, provided a reminder on the distribution and use of monoclonal antibody treatments. Please see below for Dr. Vuppalanchi’s article:
The U.S. Department of Health and Human Services (HHS) transitioned from the direct ordering process for MAB to a state-coordinated distribution system, similar to that used from November 2020 to February 2021.
LTC facilities or pharmacies with capability to provide monoclonal antibody (MAB), please complete this REDCap survey to be added to the Indiana Department of Health’s monoclonal antibody therapeutics distribution list.
This survey collects information required by AmerisourceBergen to pre-register facilities. A state pharmacy license number or letter of authorization (LOA) is required to register with AmerisourceBergen. If your facility does not have a state pharmacy license number, please complete the blank LOA form embedded in the survey and upload the completed form.
Facilities added to the distribution list will be sent a unique link each week to request MAB. Please make sure to fill out the request by the Wednesday deadline each week. Allocations will be determined based on the state’s weekly allocation from HHS.
Facilities and pharmacies that do not have the capability to administer MAB onsite should please use the National Infusion Center Association COVID-19 locator tool (not compatible with Internet Explorer) to find a location that can administer.
Monoclonal antibody therapy (MAB) can be helpful to prevent clinical deterioration and hospitalization in confirmed COVID-19 cases. MAB therapy is available under emergency use authorization for those who meet ALL the following criteria:
MAB is authorized for post exposure prophylaxis